Literature DB >> 6967194

l-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with 'therapy-resistant' depressions.

L J van Hiele.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967194     DOI: 10.1159/000117757

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


× No keyword cloud information.
  5 in total

1.  An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women.

Authors:  Brent M Kious; Hana Sabic; Young-Hoon Sung; Douglas G Kondo; Perry Renshaw
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153

2.  Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept.

Authors:  Jacob P R Jacobsen; Adrianna Oh; Rachel Bangle; Wendy L Roberts; Elizabeth L Royer; Nathan Modesto; Sonora A Windermere; Zixuan Yi; Rebecca Vernon; Manuel Cajina; Nikhil M Urs; Joshua C Snyder; Peter J Nicholls; Benjamin D Sachs; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2019-04-29       Impact factor: 7.853

Review 3.  Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

Authors:  Jacob P R Jacobsen; Andrew D Krystal; K Ranga R Krishnan; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2016-09-28       Impact factor: 14.819

Review 4.  Complementary and alternative medicine therapies to promote healthy moods.

Authors:  Kathi J Kemper; Scott Shannon
Journal:  Pediatr Clin North Am       Date:  2007-12       Impact factor: 3.278

5.  5-HTP efficacy and contraindications.

Authors:  Marty Hinz; Alvin Stein; Thomas Uncini
Journal:  Neuropsychiatr Dis Treat       Date:  2012-07-19       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.